Search
Piclidenoson
go.drugbank.com/drugs/DB05511InvestigationalIt is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome. … CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedIt is currently marketed in Canada by Valeant under the tradename Cophylac.
Zilpaterol
go.drugbank.com/drugs/DB11479ExperimentalVet approvedZilpaterol is typically fed to cattle in the last three to six weeks of life with a brief washout period to clear the drug from the tissues before slaughter. … Zilpaterol is a β2 adrenergic agonist sold under the trade name, Zilmax, produced by Intervet, a subsidiary of Merck & Co.
gp209-2M antigen
go.drugbank.com/drugs/DB17462InvestigationalThe gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.
EXOB-001
go.drugbank.com/drugs/DB18257ExperimentalEXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Danofloxacin
go.drugbank.com/drugs/DB11393ExperimentalVet approvedDanofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.
S-adenosyl-L-homocysteine
go.drugbank.com/drugs/DB01752ExperimentalFormed from S-adenosylmethionine after transmethylation reactions.
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalIt is being developed by Ascent Therapeutics. … Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia.
Tranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.